13 Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30... READ MORE December Tessa Therapeutics today announced clinical data from the pilot stage of the ongoing Phase 2 CHARIOT... 11 Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off t... READ MORE December Tessa Therapeutics today announced clinical data from an ongoing Phase 1 study (NCT04288726) of TT11... 03 Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Ther... READ MORE November Tessa Therapeutics today announced that data from its ongoing autologous and allogeneic cell therapy... 23 Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular ... READ MORE June Tessa Therapeutics today announced a collaboration agreement with the Agency for Science Technology ... 14 Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial o... READ MORE May Tessa Therapeutics today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (... 07 Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured... READ MORE May Tessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of ... 30 Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relaps... READ MORE April Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial (NCT04... 10 Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase ... READ MORE February Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (...
